Dolapo

MD| IM resident| @accintouch IM program| Aspiring 🫀

[Dolapo @_ottun]

@BerchmannMD @berchiek @misberch @DrDamluji @Sfugarmd @EdyOkoh @LenGe_MAN @sahmIbrah Congratulations 🎉 🎉

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

#VESALIUS-CV is the first large-scale randomized trial of a PCSK9 inhibitor (evolocumab) in primary prevention, showing that aggressive LDL-C lowering reduces first major cardiovascular events in patients without prior MI or stroke.

This confirms that atherosclerotic risk begins well before the 1st event & can be safely modified.

Congratulations to these investigators for this important study #AHA25 #LBCT #CVPrev #CardioTwitter

[Sek Kathiresan MD @skathire]

PCSK9 inhibition (evolocumab) saves lives.

25% relative risk reduction (3-point MACE; coronary heart disease death, MI, ischemic stroke)

20% reduction in overall mortality!!!

12,257 patients, all without prior ASCVD event; 55% LDL-C reduction from median xxx to 45 mg/dl

https://t.co/Y8ibA2sYGd

Congratulations @jaybradner @Amgen

[Dolapo @_ottun]

Meeting highlights include the JCF interactive session that looked at the joint statement of ASPC/HFSA for heart failure prevention moderated by @dranulala and @QuentinYoumans . Important point was Albuminuria is an important but under recognized predictor of heart failure .

[Dolapo @_ottun]

A week ago at HFSA 2025 presenting one of our abstracts. Special thanks to our incredible team and my program for the support .

[HFSA @HFSA]

🚨 Just released in @JCardFail - the @HFSA HF Stats 2025 report!

💔1 in 4 Americans will develop heart failure in their lifetime
💲Costs could soar to $858B by 2050

📖 Read the report ➡️ https://t.co/RFlz50Ribq
📺 Watch the highlights w/ @gcfmd ➡️ https://t.co/uwMnbbLHxc

#HFStats2025 #heartfailurestats

[Shikha Jha M.D.🫀 @Shikha_Cardio]

#ESC2025 Late Breaking Clinical Trials ⭐️
One LINER SUMMARY: At a glance 📸🫀
Outstanding amount of research♥️
Trailblazing scientific advances 🙌
#ESCCongress #WCCardio
@JACCJournals @ACCinTouch @NEJM @TheLancet @JAMA_current @CardioNerds

[Ahmed Ammar @Dr_Ahmed_Ammar]

REFINE ICD trial

Very important study, answering very critical question

⬇️⬇️⬇️

Prophylactic ICD didn’t reduce mortality or SCD post MI in patients with persistent LVEF 36-50% and abnormal autonomic tone/ cardiac reploarisation on holter

#ESCCongress
#EPeeps

[NEJM @NEJM]

Presented at #ESCCongress:

In patients with heart failure and reduced ejection fraction who were receiving guideline-directed medical therapy, digitoxin lowered the risk of death or hospitalization for heart failure as compared with placebo. Full DIGIT-HF phase 4 trial results: https://t.co/qak9UrgAhz

@escardio

[NEJM @NEJM]

Presented at #ESCCongress:

In older patients with frailty who were receiving antihypertensive drugs and had a systolic blood pressure below 130 mm Hg, reducing antihypertensive drugs did not lead to lower all-cause mortality over 4 years than usual care. Full RETREAT-FRAIL trial results: https://t.co/xRdZMaEAYd

@escardio

[American College of Cardiology @ACCinTouch]

Digitoxin + GDMT reduced the risk of a composite of all-cause death and hospitalization for worsening #HeartFailure among patients with advanced HF and HFrEF, based on findings from the DIGIT-HF trial presented at #ESCCongress. Read the news story🔗 https://t.co/89286cn00J

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

#ESCCongress #LBCT #PHYSIOSyncHF

⚡️compared conduction pacemaker vs BiV pacemaker in HFrEF with LBBB
⚡️>50% women, 💯 follow up! 👏🏽👏🏽
⚡️primary Endpoint: worse outcomes in conduction ppm 🆚 BiV ppm: conduction pacing was shown to be inferior to BiV pacing in HFrEF +LBBB

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

#HOTLINE #LBCT #ESCCongress #DIGITHF

DIGIT-HF: Digitoxin in Patients with Heart Failure & Reduced Ejection Fraction
🫀DIG trial from many years ago showed no diff in mortality but better CV mortality with digoxin (but dig >1 assoc with worse outcomes)- no trials since!
🫀trial of HFeEF (EF<\=30%), 1250 pts, Dig 0.07mg 🆚 placebo: 20% female,70% class3/4 HF, <20% on SGLT2i
🫀18% ⬇️ in primary endpoint, including significant ⬇️ all-cause mortality in Dig Tx arm vs placebo
🫀No diff in adverse events
📎 @nejm https://t.co/op5T2V44UO

[Aaron Troy, MD MPH @AaronTroyMD]

Always an honor working with @rblument1 and Stacey Schott, especially to extract our highest-yield takeaways from the just-released @American_Heart @ACCinTouch 2025 High Blood Pressure Guideline to promote healthy CV aging! @hopkinsheart https://t.co/3Fs9bKgtpp

[Ami Bhatt, MD @AmiBhattMD]

✅ Bottom line: Earlier, comprehensive, lifestyle-driven care = healthier hearts &amp; healthier brains.
#Cardiology #Prevention #BloodPressure @ACCinTouch @AmericanHeart

[Ami Bhatt, MD @AmiBhattMD]

5️⃣ Across the lifespan:
Pregnancy &amp; postpartum care get stronger emphasis.
Treat chronic HTN at ≥140/90 in pregnancy.
Monitor after delivery for lasting impact.

[Ami Bhatt, MD @AmiBhattMD]

4️⃣ Protecting the brain:
BP control isn’t just about the heart.
New evidence links tighter control with lower risk of cognitive decline &amp; dementia.
Prevention today protects tomorrow.
https://t.co/Ff0VbVYvhD

[Ami Bhatt, MD @AmiBhattMD]

3️⃣ Lifestyle is medicine:

Sodium &lt;2,300 mg/day (goal &lt;1,500)

DASH diet (fruits, veg, whole grains, lean proteins)

75–150 min/wk exercise

Stress management (yoga, breathing, meditation)

Home BP monitoring

[Ami Bhatt, MD @AmiBhattMD]

2️⃣ Alcohol:
Guidelines now emphasize zero is best.
Even small amounts raise BP.
Moderation still permitted (≤1 drink/day women; ≤2 men), but abstinence = ideal.

[Ami Bhatt, MD @AmiBhattMD]

1️⃣ Earlier intervention:
Stage 1 HTN (130–139/80–89) → lifestyle changes immediately.
If still elevated after 3–6 months → start meds.
No more “wait and see” at 140.